Skip to main content

Table 1 Clinical characteristics of the 167 patients with initial diagnosis of NMIBC

From: Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer

Characteristic Case (n = 167) Control (n = 105)
Age, yrs.
 Median 67 53
 Range 28–85 23–81
Sex, no. (%)
 Male 135 (80.8) 52 (49.5)
 Female 32 (19.2) 53 (50.5)
Smoking History, no. (%)
 Current smoker 38 (22.8) NA
 Former smoker 58 (34.7) NA
 Non-smoker 67 (40.1) NA
 Missing 4 (2.4)  
Cytology, no. (%)
 Negative/Positive/Suspicious 123 (73.6)/8 (4.8)/6 (3.6) 105 (100)
 Missing 30 (18.0)  
Tumor Stage, no. (%)
 pTa/pT1/CIS 126 (75.4)/25 (15.0)/6 (3.6) NA
 Other 10 (6.0) NA
Tumor Grade, no. (%)
 Low/High 100 (59.9)/67 (40.1) NA
Risk Categories, no. (%)
 Low/Intermediate/High 40 (24.0)/56 (33.5)/71 (42.5) NA